Minnesota Senate Bill SF4062

Minnesota 2025-2026 Regular Session

• Introduced: 3/2/26
• Refer: 3/2/26

Caption

Prohibit the use of spread pricing by pharmacy benefit managers

Impact

If enacted, SF4062 would impose stricter regulatory measures on PBMs, including the obligation to operate with greater transparency regarding costs and pricing structures. The legislation mandates that pharmacists be reimbursed at rates that reflect actual acquisition costs, effectively limiting the financial margins PBMs can impose. Additionally, it would require PBMs to disclose any ownership interests and operational details that may present conflicts of interest. The overall goal of this bill is to ensure that consumers and healthcare providers have fair access to affordable medications.

Summary

SF4062 is a legislative proposal aimed at prohibiting spread pricing practices by pharmacy benefit managers (PBMs) in Minnesota. The bill seeks to amend several sections of the Minnesota Statutes relating to the operations of PBMs, particularly in how they manage costs associated with prescription medications. Spread pricing occurs when a PBM charges a health plan one price for a prescription drug while paying a different price to the pharmacy, thereby retaining the difference as profit. This practice has faced considerable scrutiny for contributing to higher costs for consumers and health plans alike.

Contention

Despite the clear intentions of the bill, there are notable points of contention surrounding its implementation. Supporters argue that it will lower costs for consumers and provide a fairer billing system for pharmacies. However, opponents may raise concerns about potential reductions in service availability or increases in administrative burdens for PBMs. Additionally, stakeholders in the pharmaceutical industry, including drug manufacturers and distributors, are likely to contribute perspectives on how such regulatory changes could affect drug pricing and availability in the marketplace.